Advertisement
Table 1 Baseline characteristics of patients and prevalence of circulating tumor cells (CTCs) according to clinicopathological variables
| Variable | All patients N = 1221 | Patients without CTCs N = 970 | Patients with CTCs N = 251 | p-valuea |
|---|---|---|---|---|
| Age (years) | 0.41b | |||
| Median | 53.0 | 53.0 | 54.0 | |
| Range | 22 - 85 | 22 - 85 | 33 - 75 | |
| Tumor stage | 0.34c | |||
| pT1 | 489 (40.0 %) | 397 (40.9 %) | 92 (36.7 %) | |
| pT2 | 652 (53.4 %) | 511 (52.7 %) | 141 (56.2 %) | |
| pT3 | 63 (5.2 %) | 47 (4.8 %) | 16 (6.4 %) | |
| pT4 | 17 (1.4 %) | 15 (1.5 %) | 2 (0.8 %) | |
| Nodal stage | 0.23c | |||
| pN0 | 422 (34.6 %) | 341 (35.2 %) | 81 (32.3 %) | |
| pN1 | 561 (45.9 %) | 446 (46.0 %) | 115 (45.8 %) | |
| pN2 | 165 (13.5 %) | 126 (13.0 %) | 39 (15.5 %) | |
| pN3 | 70 (5.7 %) | 54 (5.6 %) | 16 (6.4 %) | |
| unknown | 3 (0.2 %) | 3 (0.3 %) | 0 (0.0 %) | |
| Histological grading | 0.30c | |||
| G1 | 59 (4.8 %) | 43 (4.4 %) | 16 (6.4 %) | |
| G2 | 604 (49.5 %) | 479 (49.4 %) | 125 (49.8 %) | |
| G3 | 557 (45.6 %) | 447 (46.1 %) | 110 (43.8 %) | |
| unknown | 1 (0.1 %) | 1 (0.1 %) | 0 (0.0 %) | |
| Histological type | 0.26d | |||
| ductal | 1019 (83.5 %) | 812 (83.7 %) | 207 (82.5 %) | |
| lobular | 122 (10.0 %) | 91 (9.4 %) | 31 (12.4 %) | |
| other | 80 (6.6 %) | 67 (6.9 %) | 13 (5.2 %) | |
| Hormone receptor status | 0.73d | |||
| negative | 368 (30.1 %) | 290 (29.9 %) | 78 (31.1 %) | |
| positive | 851 (69.7 %) | 678 (69.9 %) | 173 (68.9 %) | |
| unknown | 2 (0.2 %) | 2 (0.2 %) | 0 (0.0 %) | |
| HER2 status | 0.88d | |||
| negative | 906 (74.2 %) | 720 (74.2 %) | 186 (74.1 %) | |
| positive | 296 (24.2 %) | 234 (24.1 %) | 62 (24.7 %) | |
| unknown | 19 (1.6 %) | 16 (1.6 %) | 3 (1.2 %) | |
| Menopausal status | 0.88d | |||
| premenopausal | 521 (42.7 %) | 415 (42.8 %) | 106 (42.2 %) | |
| postmenopausal | 700 (57.3 %) | 555 (57.2 %) | 145 (57.8 %) | |
| Type of surgery | 0.27d | |||
| breast conserving | 876 (71.7 %) | 703 (72.5 %) | 173 (68.9 %) | |
| mastectomy | 345 (28.3 %) | 267 (27.5 %) | 78 (31.1 %) | |
| Radiotherapy | 1.00d | |||
| no | 175 (14.3 %) | 139 (14.3 %) | 36 (14.3 %) | |
| yes | 1045 (85.6 %) | 830 (85.6 %) | 215 (85.7 %) | |
| unknown | 1 (0.1 %) | 1 (0.1 %) | 0 (0.0 %) | |
| Endocrine therapy | 0.81d | |||
| no | 333 (27.3 %) | 266 (27.4 %) | 67 (26.7 %) | |
| yes | 887 (72.6 %) | 703 (72.5 %) | 184 (73.3 %) | |
| unknown | 1 (0.1 %) | 1 (0.1 %) | 0 (0.0 %) | |
| HER2-targeted therapy | 0.54d | |||
| no | 965 (79.0 %) | 770 (79.4 %) | 195 (77.7 %) | |
| yes | 255 (20.9 %) | 199 (20.5 %) | 56 (22.3 %) | |
| unknown | 1 (0.1 %) | 1 (0.1 %) | 0 (0.0 %) |
